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Abstract Next-generation sequencing (NGS) technology
is increasingly utilized to identify therapeutic targets for
patients with malignancy. This technology also has the
capability to reveal the presence of constitutional genetic
alterations, which may have significant implications for
patients and their family members. Here we present the
case of a 23 year old Caucasian patient with recurrent
undifferentiated sarcoma who had NGS-based tumor ana-
lysis using an assay which simultaneously analyzed the
entire coding sequence of 236 cancer-related genes (3769
exons) plus 47 introns from 19 genes often rearranged or
altered in cancer. Pathogenic alterations were reported in
tumor as the predicted protein alterations, BRCA2
‘‘R645fs*1500 and MLH1 ‘‘E694*’’. Because constitutional
BRCA2 and MLH1 gene mutations are associated with
Hereditary Breast Ovarian Cancer Syndrome (HBOCS)
and Lynch syndrome respectively, sequence analysis of
DNA isolated from peripheral blood was performed. The
presence of the alterations, BRCA2 c.1929delG and MLH1
c.2080G[T, corresponding to the previously reported
predicted protein alterations, were confirmed by Sanger
sequencing in the constitutional DNA. An additional DNA
finding was reported in this analysis, MLH1 c.2081A[C at
the neighboring nucleotide. Further evaluation of the
family revealed that all alterations were paternally in-
herited and the two MLH1 substitutions were in cis, more
appropriately referred to as MLH1 c.2080_2081del-
GAinsTC, which is classified as a variant of uncertain
significance. This case illustrates important considerations
related to appropriate interpretation of NGS tumor results
and follow-up of patients with potentially deleterious
constitutional alterations.
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Introduction
Increasingly, oncologists and pathologists are using next-
generation sequencing assays to identify potential therapeutic
targets that may help successfully treat malignancy. Multiple
oncology trials to assess the utility of next-generation se-
quencing (NGS) assays are underway [1]. Although NGS
assays are intended to provide information about acquired
genomic alterations in tumor DNA, it is acknowledged that
constitutional alterations may also be identified. Here we
present the case of a 23 year old Caucasian patient with
recurrent undifferentiated sarcoma, where tumor profiling
reported pathogenic alterations in BRCA2 and MLH1. Con-
stitutional analysis confirmed a pathogenic BRCA2 alteration
and led to reclassification of theMLH1 alteration as a variant
of uncertain significance.
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Materials and methods
A 20 year old Caucasian female first presented with a
progressively enlarging, painless left sided anterior chest
wall mass above her left breast. Computed tomography was
performed demonstrating a 3 9 3 cm mass arising anterior
to her left second rib with erosion into the rib and extension
into the pleural space. Surgical removal of the tumor was
performed with pathology demonstrating a high grade un-
differentiated sarcoma. The patient received post-operative
radiotherapy (6000 cGy) and adjuvant chemotherapy with
ifosfamide and doxorubicin.
Eleven months after completion of the initial treatment
course, the patient re-presented with severe lower back and
left leg pain and a new palpable skull mass. Imaging con-
firmed new masses, including a 5 cm tumor in her left sacral
ala and a 4.5 cm lesion in her left parietal skull. The sacral
lesion was re-biopsied and confirmed recurrence of her ori-
ginal undifferentiated sarcoma. Chemotherapy was reinitiat-
ed with three cycles of ifosfamide, carboplatin, and etoposide
(ICE) along with palliative radiotherapy (3900 cGy). Be-
cause she was judged to be at high risk for subsequent re-
currence, she received maintenance chemotherapy. She
completed 9 months of treatment before a pleural based le-
sion was noted in her right thorax. Surgical removal was
performed to remove the lesion, and pathologywas consistent
with her prior resections.
In an effort to identify therapies that might directly
target the molecular profile of her tumor, a commercial
next-generation sequencing assay as described by Framp-
ton et al. [2], was ordered. This assay simultaneously
analyzes the entire coding sequence of 236 cancer-related
genes plus 47 introns from 19 genes often rearranged or
altered in cancer. All classes of genomic alterations (base
substitutions, insertions and deletions, copy number var-
iations and rearrangements) are detectable with this assay.
Results
Two pathogenic genomic alterations were reported from
tumor testing, listed on the report as BRCA2 ‘‘R645Efs*1500
and MLH1 ‘‘E694*’’. The report stated that ‘‘the BRCA2
mutation is expected to lead to premature truncation of the
Brca2 protein prior to the area of Rad51 binding and the
DNA binding domain. This mutation is therefore predicted
to be inactivating…Therefore, in the appropriate clinical
context, testing for the presence of germline mutations in
BRCA2 is recommended.’’ The report stated that the
MLH1 mutation, ‘‘E694*’’, ‘‘observed in this tumor results
in a truncation of the 756-amino acid Mlh1 protein at
amino acid 700. This mutation is expected to result in the
loss of part of the C-terminal domain required for Pms2
binding and formation of the MutLalpha complex. Trun-
cation of MLH1 at amino acid 749–750 impairs the ability
of Mlh1 to act in error correction, checkpoint signaling and
Pms2 interaction and stabilization…Germline MLH1 mu-
tations are associated with Lynch syndrome, which is
manifested by increased risk of a number of cancers,
especially colorectal carcinoma. Therefore, in the appro-
priate clinical context, germline testing of MLH1 is
recommended.’’
There are no clinically available therapies to target these
gene mutations. Poly (ADP-ribose) Polymerase (PARP)
inhibitors, which facilitate DNA double stranded break
repair, are currently being studied in clinical trials and
recent studies suggest that cells with inactivation of Brca2
may be sensitive to PARP inhibitors [3].
Because the presence of constitutional mutations in
BRCA2 and/or MLH1 has significant implications for the
patient and family members, a genetic consultation was
recommended. A four generation pedigree was obtained by
a licensed genetic counselor (Fig. 1). The patient’s mother
reported ovarian cancer at age 42, discovered incidentally
when hysterectomy was performed for endometriosis. A
maternal uncle had testicular cancer at age 19, a maternal
aunt had recurrent basal cell carcinoma (total six; onset
50 s), and the maternal grandmother had bilateral breast
cancer resulting in double mastectomy at age 42. Colon,
breast, lung and prostate cancer at typical ages of onset
(60–70 s) was reported in maternal great grandparents and
great aunts and uncles. The patient’s paternal family his-
tory included one aunt with unilateral breast cancer at age
41, a paternal first cousin with melanoma (diagnosed 42)
and unspecified abdominal tumor, and a paternal grand-
mother with cervical or uterine cancer at age 58. The
ethnicity of the family was reported as German and Irish
(maternal) and unspecified European (paternal) with no
consanguinity. No one in the family was known to have
had genetic testing, or immunohistochemical/microsatellite
instability testing of tumors previously. Pathology records
for family members were requested but were not able to be
obtained.
Given the mother’s diagnosis of ovarian cancer at age 42
and the maternal grandmother’s diagnosis of bilateral
breast cancer, the maternal family history meets National
Comprehensive Cancer Network (NCCN) clinical criteria
for HBOCS [4, 5]. The family history does not meet
Amsterdam I, II or revised Bethesda criteria for Lynch
syndrome. The paternal family history does not meet cri-
teria for HBOCS or Lynch syndrome.
After genetic counseling, the patient elected to have
DNA analysis performed on a blood sample for targeted
analysis of the BRCA2 and MLH1 alterations. The tumor
profiling report was sent along with the patient’s blood
sample to a CLIA-certified laboratory specializing in
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constitutional genomic analysis. Through consultation with
the tumor testing laboratory, it was determined the protein
alterations reported through tumor profiling were predicted
based on the following DNA findings: c.1929delG in
BRCA2 and c.2080G[T in MLH1. Testing was performed
using targeted PCR-based amplification of the relevant
coding exon followed by dideoxy termination (Sanger)
sequencing. This testing confirmed the presence of these
alterations in DNA isolated from peripheral blood, sug-
gesting that the abnormalities were constitutional in nature.
In addition, a variant in the neighboring basepair of MLH1
(c.2081A[C) was detected which in and of itself would be
predicted to result in the amino acid substitution
p.Glu694Ser. Retrospective review of the tumor profiling
report found this alteration included in the appendix as
MLH1 ‘‘E694S’’ under ‘‘variants of unclear significance
(VUS)’’ along with seven other alterations. That this al-
teration was neighboring to the reported c.2080G[T, or the
phase (cis or trans), was not specifically noted on the tumor
profiling report.
Constitutional genetic testing for the patient’s BRCA2
andMLH1 alterations was recommended for all first-degree
relatives. The patient’s mother was tested through a CLIA-
certified laboratory and found to be negative for the BRCA2
mutation, and both MLH1 alterations. Given the family
history, repeat analysis was requested and produced the
same results. Subsequently, the patient’s father was tested,
revealing that he had the BRCA2 c.1929delG pathogenic
mutation, as well as both MLH1 alterations. Confirmation
that both MLH1 changes were paternally inherited and this
located on the same chromosome (cis) led to revised
nomenclature and re-interpretation. Because Sanger se-
quencing was used in the setting of confirmatory testing,
phase was determined through familial analysis. However,
retrospective analysis of NGS-based sequencing data also
confirmed the presence of these alterations in cis (data not
shown).
The two previously reported neighboring single basepair
subsitutitons in MLH1 actually represent an insertion-
deletion (indel) event which is most accurately described as
c.2080_2081delGAinsTC. This alteration is in-frame and is
predicted to result in the substitution of a serine for glu-
tamic at position 694, but not to lead to a premature protein
truncation. These amino acids have similar properties. This
variant has not been reported in the literature, locus-
specific databases, nor population based cohorts in the
Database of Single Nucleotide Polymorphisms (dbSNP),
NHLBI Exome Sequencing Project (ESP) or the 1000
Genomes Project. To date, this alteration has been detected
with an allele frequency of approximately 0.01 % in the
testing laboratory’s clinical cohort (greater than 13,000
alleles tested including the proband and her father). Using
the MAPP-MMR variant prediction tool, this alteration
received a score of 3.010; scores between 3.0 and 5.0 are
considered borderline/inconclusive [6]. Based on the cur-
rent evidence, this alteration present in both the proband
and her father is best classified as a variant of uncertain
significance.
The patient’s mother went on to have comprehensive
genetic testing with a NGS panel of 23 genes (ATM, BARD1,
BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1,
MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2,
PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11, and
TP53). Full gene sequencing and analysis of all coding do-
mains plus at least 5 bases into the 50 and 30 ends of all the
introns and untranslated regions (50UTR and 30UTR) was
Fig. 1 Pedigree. Age at diagnosis listed above current age. Ov ovarian, Bil Br bilateral breast, Br breast
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performed for 22 of the 23 genes (excluding EPCAM). Gross
deletion/duplication analysis was performed for all 23
genes. This panel was negative for pathogenic alterations.
Discussion
There is increasing recognition that ‘‘tumor-only’’ NGS
may reveal constitutional mutations, creating ethical
quandaries [7, 8]. In this case, tumor sequencing led to the
discovery of a pathogenic constitutional BRCA2 mutation,
and a MLH1 alteration, initially misclassified as patho-
genic, but later reinterpreted as a variant of uncertain sig-
nificance. This highlights the importance of evaluating a
DNA sequence variant not in isolation in the context of
surrounding sequence, as well as the value of using NGS-
based data to determine phase when multiple nearby vari-
ants are identified. The reclassification of the MLH1 al-
teration created specific genetic counseling challenges.
Initially, the patient was counseled that she had patho-
genic constitutional alterations of BRCA2 and MLH1,
based on tumor and constitutional sequencing results.
Several case reports describe the phenotype of patients
with digenic mutations [9–12] and a review of these cases
suggests there is a significantly increased risk for cancer,
including a high risk of multiple primary tumors [12].
Since surveillance guidelines are not established for those
with digenic mutations, National Comprehensive Cancer
Network (NCCN) Screening Guidelines for HBOCS and
Lynch syndromes was initially advised for our patient [4,
5]. Reclassification of the MLH1 alteration led to revised
genetic counseling regarding the patient’s cancer risks and
risks to relatives and altered management recommenda-
tions (HBOCS guidelines only).
Another unanticipated finding was that despite the pa-
tient’s maternal family history meeting clinical criteria for
HBOCS, testing revealed that the BRCA2 mutation was
paternally inherited. The maternal family history remains
unexplained. The father was informed of his associated
risks of breast, prostate and other cancers [13, 14]. Genetic
testing is relevant for his at risk relatives, including his
sister who was diagnosed at 41 with breast cancer, since
studies suggest that woman with BRCA2 mutations have an
increased risk of contralateral breast cancer in the absence
of intervention [15] and that the risk of ovarian, primary
peritoneal and fallopian tube cancer is 11–18 % by age 70
[16, 17]. However, the father remains reluctant to com-
municate results to relatives, creating conflict regarding
duty to warn at risk relatives, and patient autonomy and
confidentiality.
In addition to illustrating complex genetic counseling
issues that may arise in tumor only gene sequencing, this
case highlights important technical considerations.
Laboratories performing tumor sequencing may apply
different protocols, bioinformatics approaches and patho-
genicity classifications when analyzing data [18]. Nomen-
clature used in somatic mutation reporting may not be
consistent nationally accepted guidelines set out by the
Human Genome Variation Society, the American College
of Medical Genetics and Genomics (ACMG), the College
of American Pathologists, or others [19, 20]. Disparate
analysis and reporting practices may lead to confusion
when constitutional testing is performed.
In this case, targeted Sanger sequencing was performed
to confirm the BRCA2 and MLH1 mutations, both reported
initially as pathogenic. A known limitation of Sanger se-
quencing is that this methodology is unable to differentiate
phase of two reported alterations, even when they are lo-
cated in the same amplicon or sequence read. Phase has
routinely been determined by follow-up testing of family
members, most notably parents or offspring. In our case,
parental testing provided additional information to properly
classify the MLH1 alteration as a variant of uncertain
significance.
It is valid to ask why the MLH1 was misclassified ini-
tially on the tumor profiling report. The phase of the two
alterations should be identified using NGS, as long as both
alterations are located within the same sequencing read
(typically within 50–200 bp depending on the protocol).
When the laboratory was contacted, they discovered that
their bioinformatics pipeline had indeed appropriately
flagged the alteration, prompting pathology review. How-
ever, human error led to misreporting in this case (personal
communication). The tumor profiling laboratory amended
the original report, after a visual review of NGS data.
As NGS sequencing is increasingly performed within
clinical and research settings, unanticipated findings will
continue to increase. As discussed by other authors,
guidelines need to be developed to provide recommenda-
tions regarding efficient pre-test counseling and informed
consent prior to tumor-only testing, as well as post-test
disclosure, while carefully considering the original intent
of testing [7, 8, 18]. As illustrated in this case, it will be
important to consider the possibility of potential follow-up
of more than one alteration that may be present constitu-
tionally. Recommendations will also need to consider
conflicts that may arise between patient autonomy and
confidentiality and duty to warn family members of known
genetic risks.
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